Nuformix plc (NFX.L)
- Previous Close
0.1200 - Open
0.0000 - Bid 0.1000 x --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.3000 - Volume
40,000 - Avg. Volume
30,459,213 - Market Cap (intraday)
2.021M - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date May 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
www.nuformix.comRecent News: NFX.L
View MorePerformance Overview: NFX.L
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NFX.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NFX.L
View MoreValuation Measures
Market Cap
2.03M
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.85%
Return on Equity (ttm)
-153.80%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-3.78M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
97.91k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-319.74k